Page 13 - Solid Biosciences News Today

Equities research analysts expect that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will post earnings per share of ($0.18) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with estimates ranging from ($0.20) to ($0.17). Solid Biosciences posted earnings of ($0.19) per share during the same quarter […]

Solid Biosciences (NASDAQ:SLDB – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage presently has a $1.25 target price on the stock. Zacks Investment Research‘s target price suggests a potential downside of 11.97% from the company’s current […]

Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) insider Carl Ashley Morris sold 22,665 shares of Solid Biosciences stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $1.10, for a total transaction of $24,931.50. The transaction was disclosed in a legal filing with the SEC, which […]

Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2022 earnings per share estimates for shares of Solid Biosciences in a research note issued on Tuesday, March 15th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings of ($0.17) per share for the […]

Solid Biosciences (NASDAQ:SLDB – Get Rating) released its earnings results on Monday. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.03, Fidelity Earnings reports. Shares of SLDB stock opened at $1.00 on Tuesday. The company has a market cap of $109.78 million, a PE ratio of […]

Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, is an X-linked recessive disease that affects approximately one in...

Orlando, Fla. (PRWEB) February 22, 2022 -- The annual Lake Nona Impact Forum will convene 300 of the brightest minds and global thought leaders in health,

BioPharma

In this edited transcript from our August 2021 executive virtual roundtable, perspectives on life science manufacturing and the supply chain are...

There is a healthy appetite for continued investment in gene therapy, in new modalities and more indications, says an industry insider as he reflected on the prospects for the US gene therapy sector next year.